Startseite Prognostic significance of serum albumin level changes in acute ischemic stroke: the role of biological and analytical variation
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Prognostic significance of serum albumin level changes in acute ischemic stroke: the role of biological and analytical variation

  • Konstantinos Makris EMAIL logo , Katerina Koniari , Loukia Spanou , Eleni Gialouri , Efimia Evodia und Moyssis Lelekis
Veröffentlicht/Copyright: 27. Juni 2015
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 54 Heft 1

Abstract

Background: Animal studies have shown a neuroprotective effect of human serum albumin (sAlb) in ischemic stroke (IS). Previous studies have shown an association of high sAlb with better outcome. Our aim is to investigate the kinetics of sAlb in acute IS and its possible correlation with outcome taking into account the analytical and biological variation of sAlb measurement.

Methods: In a prospective observational study, we enrolled 105 patients with acute IS. sAlb was measured upon admission, at 24 h, 48 h, 72 h and Day 7 thereafter. Stroke severity was assessed upon admission and at 72 h, and functional outcome on Day 7. Patients were divided into two groups according to functional outcome on discharge. Calculation of reference change value was used to assess the clinical significance of sAlb changes and multiple logistic regression to assess the independent association between variables and outcome.

Results: Fifty-one patients (48.6%) had poor outcome. Their sAlb levels exhibit a significant daily decrease until 72 h (35.9 g/L) compared to baseline (41.1 g/L) and remained low until Day 7 (36.0 g/L). These changes were clinically significant only from 72 h on. Among non-poor outcome patients a significant daily decrease until 72 h (40.9 g/L) was followed by recovery on Day 7 (41.2 g/L), but these changes were not clinically significant. sAlb was not independently associated with the functional outcome at any time-point.

Conclusions: This study shows that sAlb levels might change during the first days after an acute IS, but these changes although statistically significant are not clinically significant if we take into account the analytical and biological variation of sAlb.

Keywords: acute ischemic stroke; analytical variation; biological variation; outcome; reference change value; serum albumin
Corresponding author: Dr. Konstantinos Makris PhD, EurClinChem, Clinical Biochemist, Laboratory of Metabolic Bone Diseases, Clinical Biochemistry Department, KAT General Hospital, 2 Nikis Street, 14561 Kifissia, Athens, Greece, Phone: +30 2132086701/ +30 6972207867, E-mail:

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Vincent JL. Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol 2009;23:183–91.10.1016/j.bpa.2008.11.004Suche in Google Scholar

2. Boldt J. Use of albumin: an update. Br J Anaesth 2010;104: 276–84.10.1093/bja/aep393Suche in Google Scholar

3. Belayev L, Zhao W, Pattany PM, Weaver RG, Huh PW, Lin B, et al. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke 1998;29:2587–99.10.1161/01.STR.29.12.2587Suche in Google Scholar

4. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32:553–60.10.1161/01.STR.32.2.553Suche in Google Scholar

5. Belayev L, Pinard E, Nallet H, Seylaz J, Liu Y, Riyamongkol P, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke 2002;33:1077–84.10.1161/hs0402.105555Suche in Google Scholar

6. Belayev L, Saul I, Busto R, Danielyan K, Vigdorchik A, Khoutorova L, et al. Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat. Stroke 2005;36:326–31.10.1161/01.STR.0000152949.31366.3dSuche in Google Scholar

7. Ginsberg MD, Palesch YY, Hill MD. The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report. Biochem Soc Trans 2006;34(Pt 6):1323–6.10.1042/BST0341323Suche in Google Scholar

8. Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke – I: physiological responses and safety results. Stroke 2006;37:2100–6.10.1161/01.STR.0000231388.72646.05Suche in Google Scholar

9. Ginsberg MD, Palesch YY, Martin RH, Hill MD, Moy CS, Waldman BD, et al. The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2. Stroke 2011;42:119–27.10.1161/STROKEAHA.110.596072Suche in Google Scholar

10. Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, et al. High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol 2013;12:1049–58.10.1016/S1474-4422(13)70223-0Suche in Google Scholar

11. Hill MD, Moy CS, Palesch YY, Martin R, Dillon CR, Waldman BD, et al. The albumin in acute stroke trial (ALIAS); design and methodology. Int J Stroke 2007;2:214–9.10.1111/j.1747-4949.2007.00143.xSuche in Google Scholar PubMed

12. Abubakar S, Sabir A, Ndakotsu M, Imam M, Tasiu M. Low admission serum albumin as prognostic determinant of 30-day case fatality and adverse functional outcome following acute ischemic stroke. Pan Afr Med J 2013;14:53.10.11604/pamj.2013.14.53.1941Suche in Google Scholar PubMed PubMed Central

13. Dziedzic T, Slowik A, Szczudlik A. Serum albumin level as a predictor of ischemic stroke outcome. Stroke 2004;35:e156–8.10.1161/01.STR.0000126609.18735.beSuche in Google Scholar PubMed

14. Idicula TT, Waje-Andreassen U, Brogger J, Naess H, Thomassen L. Serum albumin in ischemic stroke patients: the higher the better. The Bergen Stroke Study. Cerebrovasc Dis 2009;28:13–7.10.1159/000215938Suche in Google Scholar PubMed

15. Multicenter trial of hemodilution in ischemic stroke – background and study protocol. Scandinavian Stroke Study Group. Stroke 1985;16:885–90.10.1161/01.STR.16.5.885Suche in Google Scholar

16. Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke 2000;31:1429–38.10.1161/01.STR.31.6.1429Suche in Google Scholar PubMed

17. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604–7.10.1161/01.STR.19.5.604Suche in Google Scholar PubMed

18. Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke 2002;33:2243–6.10.1161/01.STR.0000027437.22450.BDSuche in Google Scholar PubMed

19. von Meyer A, Pick K-H, Jurgen H. Nachevaluierung des refenzbereiches fur albumin in serum/plasma mit farbstoffbindungsmethoden (bromkresolgrun und bromkresolpurpur). J Lab Med 2010;34:155–7.Suche in Google Scholar

20. Fraser C. Biological variation: from principles to practice. Washington, DC: AACC press, 2001.Suche in Google Scholar

21. Minchinela J, Ricós C, Perich C, Fernández-Calle P, Alvarez V, Domenech M, et al. Biological variation database, and quality specifications for imprecision, bias and total error (desirable and minimum). The 2012 update. Available from: http://www.westgard.com/biodatabase-2012-update.htm. Accessed on January 15, 2015.Suche in Google Scholar

22. Gillum RF, Ingram DD, Makuc DM. Relation between serum albumin concentration and stroke incidence and death: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1994;140:876–88.10.1093/oxfordjournals.aje.a117176Suche in Google Scholar PubMed

23. Reinhart WH, Nagy C. Albumin affects erythrocyte aggregation and sedimentation. Eur J Clin Invest 1995;25:523–8.10.1111/j.1365-2362.1995.tb01739.xSuche in Google Scholar PubMed

24. Halliwell B. Albumin – an important extracellular antioxidant? Biochem Pharmacol 1988;37:569–71.10.1016/0006-2952(88)90126-8Suche in Google Scholar

25. Wasil M, Halliwell B, Hutchison DC, Baum H. The antioxidant action of human extracellular fluids. Effect of human serum and its protein components on the inactivation of alpha 1-antiproteinase by hypochlorous acid and by hydrogen peroxide. Biochem J 1987;243:219–23.10.1042/bj2430219Suche in Google Scholar

26. Zoellner H, Höfler M, Beckmann R, Hufnagl P, Vanyek E, Bielek E, et al. Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. J Cell Sci 1996;109:2571–80.10.1242/jcs.109.10.2571Suche in Google Scholar

27. Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J Neurosurg 1997;87:595–601.10.3171/jns.1997.87.4.0595Suche in Google Scholar

28. Huh PW, Belayev L, Zhao W, Busto R, Saul I, Ginsberg MD. The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res 1998;804:105–13.10.1016/S0006-8993(98)00674-XSuche in Google Scholar

29. Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke – II: Neurologic outcome and efficacy analysis. Stroke 2006;37:2107–14.10.1161/01.STR.0000231389.34701.b5Suche in Google Scholar PubMed

30. Ricós C, Cava F, García-Lario JV, Hernández A, Iglesias N, Jiménez CV, et al. The reference change value: a proposal to interpret laboratory reports in serial testing based on biological variation. Scand J Clin Lab Invest 2004;64:175–84.10.1080/00365510410004885Suche in Google Scholar PubMed

31. Ricós C, Iglesias N, García-Lario JV, Simón M, Cava F, Hernández A, et al. Within-subject biological variation in disease: collated data and clinical consequences. Ann Clin Biochem 2007;44:343–52.10.1258/000456307780945633Suche in Google Scholar PubMed

32. Bouziana SD, Tziomalos K. Malnutrition in patients with acute stroke. J Nutr Metab 2011;2011:167898.Suche in Google Scholar

33. Dávalos A, Ricart W, Gonzalez-Huix F, Soler S, Marrugat J, Molins A, et al. Effect of malnutrition after acute stroke on clinical outcome. Stroke 1996;27:1028–32.10.1161/01.STR.27.6.1028Suche in Google Scholar PubMed

34. Yoo SH, Kim JS, Kwon SU, Yun SC, Koh JY, Kang DW. Undernutrition as a predictor of poor clinical outcomes in acute ischemic stroke patients. Arch Neurol 2008;65:39–43.10.1001/archneurol.2007.12Suche in Google Scholar PubMed

35. Sánchez-Moreno C, Jiménez-Escrig A, Martín A. Stroke: roles of B vitamins, homocysteine and antioxidants. Nutr Res Rev 2009;22:49–67.10.1017/S0954422409990023Suche in Google Scholar PubMed

Received: 2015-3-22
Accepted: 2015-5-27
Published Online: 2015-6-27
Published in Print: 2016-1-1

©2016 by De Gruyter

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Building a bridge to safe diagnosis in health care. The role of the clinical laboratory
  4. Capillary electrophoresis for the screening and diagnosis of inherited hemoglobin disorders. Ready for prime time?
  5. Reviews
  6. Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis
  7. Towards biomarker-based tests that can facilitate decisions about prevention and management of preeclampsia in low-resource settings
  8. Mini Review
  9. Clinical relevance of sST2 in cardiac diseases
  10. General Clinical Chemistry and Laboratory Medicine
  11. Preservation of urine free catecholamines and their free O-methylated metabolites with citric acid as an alternative to hydrochloric acid for LC-MS/MS-based analyses
  12. Performance characteristics of the VIDAS® 25-OH Vitamin D Total assay – comparison with four immunoassays and two liquid chromatography-tandem mass spectrometry methods in a multicentric study
  13. Differentiation of acute pyelonephritis from other febrile states in children using urinary neutrophil gelatinase-associated lipocalin (uNGAL)
  14. Early postoperative C-terminal agrin fragment (CAF) serum levels predict graft loss and proteinuria in renal transplant recipients
  15. Homocitrulline: a new marker for differentiating acute from chronic renal failure
  16. Hematology and Coagulation
  17. Development of hemoglobin typing control materials for laboratory investigation of thalassemia and hemoglobinopathies
  18. Comparison of capillary electrophoresis and high performance liquid chromatography for detection and quantification of hemoglobin New York
  19. Prevalence of hemostatic alterations in patients with recurrent spontaneous subconjunctival hemorrhage
  20. Reference Values and Biological Variations
  21. Reference intervals for 24 laboratory parameters determined in 24-hour urine collections
  22. First trimester PAPP-A2, PAPP-A and hCGβ in small-for-gestational-age pregnancies
  23. Cancer Diagnostics
  24. Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients
  25. Cardiovascular Diseases
  26. Time from symptom onset influences high-sensitivity troponin T diagnostic accuracy for the diagnosis of acute myocardial infarction
  27. Prognostic significance of serum albumin level changes in acute ischemic stroke: the role of biological and analytical variation
  28. Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population
  29. Infectious Diseases
  30. Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin
  31. Diabetes
  32. Performance of strip-based glucose meters and cassette-based blood gas analyzer for monitoring glucose levels in a surgical intensive care setting
  33. Accuracy and precision assessment of a new blood glucose monitoring system
  34. Acknowledgment
  35. Acknowledgment
  36. Letter to the Editors
  37. Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker
  38. Platelet microRNAs are not modulated by systemic heparin in acute coronary syndromes
  39. Concomitant appearance of two false positive peaks with a true monoclonal one in a patient with plasma cell myeloma
  40. Anti-streptavidin interferences in Roche thyroid immunoassays: a case report
  41. Evaluation of the new Methotrexate CMIA assay on the Architect i2000SR
  42. Liposomal interference on Sysmex XN-series body fluid mode
  43. Development of an immunomagnetic beads-based test and its application in influenza surveillance
https://doi.org/10.1515/cclm-2015-0281
Schlagwörter für diesen Artikel
acute ischemic stroke; analytical variation; biological variation; outcome; reference change value; serum albumin

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Building a bridge to safe diagnosis in health care. The role of the clinical laboratory
  4. Capillary electrophoresis for the screening and diagnosis of inherited hemoglobin disorders. Ready for prime time?
  5. Reviews
  6. Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis
  7. Towards biomarker-based tests that can facilitate decisions about prevention and management of preeclampsia in low-resource settings
  8. Mini Review
  9. Clinical relevance of sST2 in cardiac diseases
  10. General Clinical Chemistry and Laboratory Medicine
  11. Preservation of urine free catecholamines and their free O-methylated metabolites with citric acid as an alternative to hydrochloric acid for LC-MS/MS-based analyses
  12. Performance characteristics of the VIDAS® 25-OH Vitamin D Total assay – comparison with four immunoassays and two liquid chromatography-tandem mass spectrometry methods in a multicentric study
  13. Differentiation of acute pyelonephritis from other febrile states in children using urinary neutrophil gelatinase-associated lipocalin (uNGAL)
  14. Early postoperative C-terminal agrin fragment (CAF) serum levels predict graft loss and proteinuria in renal transplant recipients
  15. Homocitrulline: a new marker for differentiating acute from chronic renal failure
  16. Hematology and Coagulation
  17. Development of hemoglobin typing control materials for laboratory investigation of thalassemia and hemoglobinopathies
  18. Comparison of capillary electrophoresis and high performance liquid chromatography for detection and quantification of hemoglobin New York
  19. Prevalence of hemostatic alterations in patients with recurrent spontaneous subconjunctival hemorrhage
  20. Reference Values and Biological Variations
  21. Reference intervals for 24 laboratory parameters determined in 24-hour urine collections
  22. First trimester PAPP-A2, PAPP-A and hCGβ in small-for-gestational-age pregnancies
  23. Cancer Diagnostics
  24. Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients
  25. Cardiovascular Diseases
  26. Time from symptom onset influences high-sensitivity troponin T diagnostic accuracy for the diagnosis of acute myocardial infarction
  27. Prognostic significance of serum albumin level changes in acute ischemic stroke: the role of biological and analytical variation
  28. Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population
  29. Infectious Diseases
  30. Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin
  31. Diabetes
  32. Performance of strip-based glucose meters and cassette-based blood gas analyzer for monitoring glucose levels in a surgical intensive care setting
  33. Accuracy and precision assessment of a new blood glucose monitoring system
  34. Acknowledgment
  35. Acknowledgment
  36. Letter to the Editors
  37. Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker
  38. Platelet microRNAs are not modulated by systemic heparin in acute coronary syndromes
  39. Concomitant appearance of two false positive peaks with a true monoclonal one in a patient with plasma cell myeloma
  40. Anti-streptavidin interferences in Roche thyroid immunoassays: a case report
  41. Evaluation of the new Methotrexate CMIA assay on the Architect i2000SR
  42. Liposomal interference on Sysmex XN-series body fluid mode
  43. Development of an immunomagnetic beads-based test and its application in influenza surveillance
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 18.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2015-0281/html
Button zum nach oben scrollen